These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 31319889)
1. Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome. Hargreaves P; Daoudlarian D; Theron M; Kolb FA; Manchester Young M; Reis B; Tiaden A; Bannert B; Kyburz D; Manigold T Arthritis Res Ther; 2019 Jul; 21(1):175. PubMed ID: 31319889 [TBL] [Abstract][Full Text] [Related]
2. In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary Sjögren's syndrome. Volchenkov R; Brun JG; Jonsson R; Appel S Arthritis Res Ther; 2013; 15(5):R114. PubMed ID: 24025795 [TBL] [Abstract][Full Text] [Related]
3. Elevated cytokine levels in tears and saliva of patients with primary Sjögren's syndrome correlate with clinical ocular and oral manifestations. Chen X; Aqrawi LA; Utheim TP; Tashbayev B; Utheim ØA; Reppe S; Hove LH; Herlofson BB; Singh PB; Palm Ø; Galtung HK; Jensen JCL Sci Rep; 2019 May; 9(1):7319. PubMed ID: 31086200 [TBL] [Abstract][Full Text] [Related]
4. Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios. Kang EH; Lee YJ; Hyon JY; Yun PY; Song YW Clin Exp Rheumatol; 2011; 29(6):970-6. PubMed ID: 22132900 [TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome. Bentley D; Fisher BA; Barone F; Kolb FA; Attley G Rheumatology (Oxford); 2023 Nov; 62(11):3644-3653. PubMed ID: 36864622 [TBL] [Abstract][Full Text] [Related]
6. T cell reactivity to Sjögren's syndrome related antigen La(SSB). Helsloot J; Sturgess A J Rheumatol; 1997 Dec; 24(12):2340-7. PubMed ID: 9415639 [TBL] [Abstract][Full Text] [Related]
7. Differential cytokine expression and regulatory cells in patients with primary and secondary Sjögren's syndrome. Furuzawa-Carballeda J; Sánchez-Guerrero J; Betanzos JL; Enriquez AB; Avila-Casado C; Llorente L; Hernández-Molina G Scand J Immunol; 2014 Dec; 80(6):432-40. PubMed ID: 25346207 [TBL] [Abstract][Full Text] [Related]
8. Autoantigen-specific B cells and plasma cells are prominent in areas of fatty infiltration in salivary glands of patients with primary Sjögren's syndrome. Skarstein K; Jensen JL; Galtung H; Jonsson R; Brokstad K; Aqrawi LA Autoimmunity; 2019; 52(7-8):242-250. PubMed ID: 31661985 [TBL] [Abstract][Full Text] [Related]
9. IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα. Bikker A; Moret FM; Kruize AA; Bijlsma JW; Lafeber FP; van Roon JA Rheumatology (Oxford); 2012 Jun; 51(6):996-1005. PubMed ID: 22302060 [TBL] [Abstract][Full Text] [Related]
11. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome. Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648 [TBL] [Abstract][Full Text] [Related]
12. Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome. Sanosyan A; Daien C; Nutz A; Bollore K; Bedin AS; Morel J; Zimmermann V; Nocturne G; Peries M; Guigue N; Gottenberg JE; Van de Perre P; Mariette X; Tuaillon E Front Immunol; 2019; 10():1153. PubMed ID: 31191532 [TBL] [Abstract][Full Text] [Related]
13. CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjögren's syndrome patients and correlates with focus score and disease activity. Alessandri C; Ciccia F; Priori R; Astorri E; Guggino G; Alessandro R; Rizzo A; Conti F; Minniti A; Barbati C; Vomero M; Pendolino M; Finucci A; Ortona E; Colasanti T; Pierdominici M; Malorni W; Triolo G; Valesini G Arthritis Res Ther; 2017 Jul; 19(1):178. PubMed ID: 28743286 [TBL] [Abstract][Full Text] [Related]
14. Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome. Chen C; Liang Y; Zhang Z; Zhang Z; Yang Z Int Immunopharmacol; 2020 Nov; 88():106878. PubMed ID: 32791244 [TBL] [Abstract][Full Text] [Related]
15. The IL33/ST2 axis in Sjogren syndrome in relation to disease activity. Margiotta DP; Navarini L; Vadacca M; Lo Vullo M; Pignataro F; Basta F; Afeltra A Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1295-9. PubMed ID: 27097949 [TBL] [Abstract][Full Text] [Related]
17. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X Scand J Immunol; 2008 Feb; 67(2):185-92. PubMed ID: 18201372 [TBL] [Abstract][Full Text] [Related]
18. Tear cathepsin S as a candidate biomarker for Sjögren's syndrome. Hamm-Alvarez SF; Janga SR; Edman MC; Madrigal S; Shah M; Frousiakis SE; Renduchintala K; Zhu J; Bricel S; Silka K; Bach D; Heur M; Christianakis S; Arkfeld DG; Irvine J; Mack WJ; Stohl W Arthritis Rheumatol; 2014 Jul; 66(7):1872-81. PubMed ID: 24644101 [TBL] [Abstract][Full Text] [Related]
19. STAT-5 is activated constitutively in T cells, B cells and monocytes from patients with primary Sjögren's syndrome. Pertovaara M; Silvennoinen O; Isomäki P Clin Exp Immunol; 2015 Jul; 181(1):29-38. PubMed ID: 25736842 [TBL] [Abstract][Full Text] [Related]
20. Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjögren's syndrome. Guggino G; Ciccia F; Raimondo S; Giardina G; Alessandro R; Dieli F; Sireci G; Triolo G Clin Exp Rheumatol; 2016; 34(1):25-31. PubMed ID: 26633038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]